Upstream Bio(NASDAQ) UPB

Upstream Bio makes new medicines for people with severe lung problems. These treatments help patients who struggle with breathing due to swelling. The company focuses on asthma and other serious respiratory conditions.

Treatments for Troubled Lungs

• Verekitug: An experimental drug designed to block specific signals that cause swelling in the lungs and airways.
• Severe Asthma Treatment: A therapy for patients whose asthma does not improve with regular inhalers or standard care.
• Chronic Sinus Therapy: A clinical program to help people with long-term sinus swelling and nasal polyps.
• COPD Therapy: A medicine being developed for chronic obstructive pulmonary disease, which makes it hard to breathe.

Milestones in Medicine

• Purchased the main drug candidate from Astellas Pharma in Oct. 2021 to start its clinical pipeline.
• Partnered with Regeneron in Oct. 2021 to manage future royalty payments and data reporting for its products.
• Signed a deal with Maruho in Oct. 2021 to develop and sell its treatments in the Japanese market.
• Licensed specialized technology from Lonza in Oct. 2021 to help with the global manufacturing of its medicines.
• Completed its initial public offering in Oct. 2024 to raise money for testing its new therapies.

How It Blocks Inflammation

The company targets a receptor for Thymic Stromal Lymphopoietin, which is a protein that triggers swelling in many lung diseases. This approach may allow for dosing every three months and could help patients who do not respond to other available therapies.

Vital Financial Signs

• Net loss was $80.3 million for the six-month period ended June 30, 2026.
• Research and development costs were $72.7 million for the six-month period ended June 30, 2026, up $9.0 million year over year.
• Cash, cash equivalents, and short-term investments totaled $261.3 million as of June 30, 2026.
• Market capitalization was $404.9 million as of the current reporting period.

The Long-Term View

Upstream Bio has grown from a startup into a public company focused on one primary drug candidate. Its development strategy depends on testing this therapy across multiple serious breathing disorders over the next several years.